Cannabis Treats Cancer and Epilepsy

Description: Medical Marijuana

Dr. Mark Sircus, Ac., OMD, DM (P)

Director International Medical Veritas Association

Doctor of Oriental and Pastoral Medicine

Dr. Sean McAllister and Pierre Desprez claim they’ve successfully used cannabidiol to fight animal genes involved in the spread of cancer. “We found this one compound had a specific effect on metastatic cancer cells, very aggressive tumor cells,” McAllister says. Cannabidiol, the research appears to show, helps shut down receptors that inhibit cancerous cells from metastasizing.  “We find when you treat with cannabidiol, you down regulate the expression of this protein, and that inhibits the disease process.” Unlike THC, the ingredient in marijuana that makes you feel stoned, cannabidiol is a non-toxic compound of the plant that has no psychoactive qualities.

I already published that marijuana is the best medicine for 3-year-old Cash Hyde of Missoula, Montana. The boy’s parent’s defied doctor’s orders—and Montana law—to get their hands on the medicinal treatment their son needed after he was diagnosed with recurring brain tumors at 22 months old. “I’ve had law enforcement threatening to kick my door down, but I would have done anything to keep Cashy alive,” said Mike Hyde, who has long been a proponent of the drug, told ABCNews.com.

My book on Medical Marijuana goes into the research from around the globe, including from Harvard University that sustains the conclusions of doctors McAllister and Desprez.

Dixie Botanicals is shipping Cannabidiol from Denver Colorado to all fifty states though of course one can grow marijuana oneself and or use regular marijuana strains if one lives in one of the now fifteen states that has made medical marijuana legal.

I take great exception to the Obama administration that has continued to resist the legalization on a federal level of medical marijuana. They still insist that there is no medical use for marijuana when all the science proves the government to be dead wrong. They hunt the world for terrorists but some of the worst live and work right in Washington DC. Terrorists are people who hurt others and I do not see the difference between those who use guns and those who use drugs or deny the population the natural substances they need to be well.

Of course marijuana is extremely effective for other diseases. The most recent I have read about: Medical pot treats boy’s epilepsy, without getting him high. The little boy has been swallowing droppers full of a solution made mostly of cannabidiol, or CBD, the second most prominent of marijuana’s 100 or so cannabinoids. Unlike the dominant THC, cannabidiol is not psychoactive, so the sweet-tasting infusion Jayden takes four times a day doesn’t make him high.

Down from 22 prescription pills per day to four, he now eats solid food, responds to his father’s incessant requests for kisses and dances in his Modesto living room to the “Yo Gabba Gabba!” theme song. The frequency and intensity of his seizures have been greatly reduced.

CBD was virtually bred out of U.S. plants decades ago by growers whose customers preferred the mind-altering properties of high-THC varietals. Yet it is experiencing a resurgence, having shown promise as an anti-inflammatory, anticonvulsant, neuroprotectant and cancer-fighting agent.

Studies have shown THC is “overwhelmingly anticonvulsant” in animals, said Dr. Ben Whalley, a researcher at Britain’s University of Reading, but CBD and some other non-psychoactive cannabinoids have shown similar effects without the mind-altering downside.”

http://drsircus.com/medicine/cancer/cannabis-treats-cancer-and-epilepsy#utm_source=Dr+Sircus+Newsletter&utm_campaign=820775ef59-Article_045&utm_medium=email

Federal Government Reports Marijuana Effective in Combatting Certain Cancers Reports ADSI – NBC News

“LOS ANGELES, March 12, 2013 (GLOBE NEWSWIRE) — The following is a statement by Advocates for the Disabled and Seriously Ill:

In a recent report, the National Cancer Institute (NCI), part of the Federal government’s National Institutes of Health (NIH), stated that marijuana “inhibited the survival of both estrogen receptor–positive and estrogen receptor–negative breast cancer cell lines.” The same report showed marijuana slows or stops the growth of certain lung cancer cells and suggested that marijuana may provide “risk reduction and treatment of colorectal cancer.”

Referring to the NCI report, Patient Rights attorney Matthew Pappas said, “The Federal government’s continuing attack on people prescribed medical cannabis by their doctors is hypocritical considering the benefits reported by its own National Cancer Institute.” Pappas represents patients in defending their right to reasonably obtain medical marijuana. The patients contend the Federal government and various municipalities are trying to prevent them from obtaining cannabis for medical purposes in direct contravention of state laws. “Cities that ban dispensaries are denying patients the ability to obtain a medicine the Federal government’s National Institutes of Health says fights cancer and they’re doing it with the Obama Administration’s help.” Recently, the City of Los Angeles repealed its ban of medical marijuana collectives after Bill Rosendahl, a member of its city council diagnosed with cancer and prescribed medical marijuana said to fellow council members about the ban, “You want to kill me? You want to throw me under the bus?”

The NCI report also examined whether patients who smoke marijuana rather than ingesting it orally are exposed to a higher risk of lung and certain digestive system cancers. According to the government, 19 studies “failed to demonstrate statistically significant associations between marijuana inhalation and lung cancer.” The report also identified a separate study of 611 lung cancer patients that showed marijuana was “not associated with an increased risk of lung cancer or other upper aerodigestive tract cancers and found no positive associations with any cancer type.” In the area of prostate cancer, the NCI report was inconclusive and suggested further research was necessary. In its report, the National Cancer Institute also identified a “study of intratumoral injection of delta-9-THC in patients with recurrent glioblastoma” that showed tumor reduction in the test participants.

Despite the Federal government sanctioned and authorized NCI report, Pappas said Congress and the Obama Administration have continued to thwart marijuana research. In an announced effort to displace state medical marijuana laws, the Office of National Drug Control Policy described “medical” marijuana as a “myth” fueling “troubling misconceptions” in documents found on its website. The Federal government appears to be focused on creating more chemical drugs, many of which are the subject of various attorney television commercials seeking out those adversely impacted by those drugs. Pappas said both the Drug Enforcement Administration and the Office of National Drug Control Policy continue to assert marijuana lacks any medicinal value despite the research showing cannabis reduces certain cancer risks and inhibits the growth of tumor cells. He also commented that the Federal government’s anti-marijuana position contributes to and encourages prejudice and public misconception about the legitimate use of medical cannabis as treatment for seriously ill patients.

In addition to anti-cancer properties, separate research reported marijuana appears to have “profound nerve-protective and brain-enhancing properties that could potentially treat many neurodegenerative disorders.” In its report, the National Cancer Institute stated cannabis effectively treats insomnia and referenced a placebo-controlled study in cancer patients showing increased quality of sleep and relaxation in those treated with tetrahydrocannabinol, an active component in marijuana.

Responding to a White House statement that only a small percentage of patients prescribed medical cannabis under state laws use it to treat cancer, Pappas said “marijuana isn’t just for cancer or AIDS patients – it can also treat, for example, sleeplessness.” Although generally not a life threatening condition, Pappas referred to insomnia as a health issue regularly treated with prescription drugs zolpidem (brand name Ambien) and eszopiclone (brand name Lunesta). According to their manufacturers’ websites, zolpidem and eszopiclone have been shown to cause severe side effects including aggressiveness, hallucinations, confusion, or suicidal thoughts. Pappas noted that, unlike those drugs, studies on insomnia similar to those reported by the National Cancer Institute show medical marijuana effectively treats insomnia at a far lower cost and with fewer side effects. Marijuana has also been prescribed for glaucoma, multiple sclerosis, chronic pain, and a variety of other physical and mental conditions.

Addressing the White House website statement that medical marijuana should remain criminally illegal under federal law, Pappas said that “with every drug, the doctor must consider the benefits versus any possible side effects. In its 3000-plus year history of medicinal use, there has never been a known, confirmed death caused by overdose of marijuana. To suggest that prescription drugs known to have severe negative side effects are alright and that marijuana can only be used for cancer or AIDS is nonsensical. It demonstrates how the Federal government’s decision to usurp state sovereignty is harming people because burdening citizens with federal criminal records based on medical marijuana provided for under state law is simply wrong. To continue outlawing the use of a drug shown to have life-saving, anti-cancer benefits that has been used safely as a medication for thousands of years is irresponsible.”

Jan., 2013 National Cancer Institute PDQ® report on cannabis:

www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional/page2

July, 2009 NIH report on cannabis reducing neck and head squamous cell carcinoma:

www.ncbi.nlm.nih.gov/pubmed/19638490

Nov., 2012 NIH report on cannabis breast cancer treatment:

www.ncbi.nlm.nih.gov/pubmed/22776349

Report on study showing smoked marijuana does not cause cancer:

www.washingtonpost.com/wp-dyn/content/article/2006/05/25/AR2006052501729.html

Report on neuroprotective benefits of marijuana:

www.foxnews.com/health/2012/03/20/researchers-study-neuroprotective-properties-in-cannabis/

White House “Fact Sheet” on Marijuana Legalization:

http://www.whitehouse.gov/sites/default/files/ondcp/Fact_Sheets/marijuana_legalization_fact_sheet_3-3-11.pdf

Office of National Drug Control Policy documents:

www.whitehouse.gov/sites/default/files/page/files/marijuana_fact_sheet_3-28-12.pdf and

www.whitehouse.gov/sites/default/files/ondcp/issues-content/medical_marijuana_information_packet.pdf

For more information, contact Advocates for the Disabled and Seriously Ill at (213) 531-1788.”

http://www.nbcnews.com/id/51148243/ns/business-press_releases/t/federal-government-reports-marijuana-effective-combatting-certain-cancers-reports-adsi/

Cannabinoids may be therapeutic in breast cancer.

“Cannabinoids are a group of compounds synthesized exclusively by the Cannabis sativa plant, commonly known as marijuana. In 1990, the first cannabinoid-specific membrane (CB1) was characterized and cloned (Matsuda, Lolait, Brownstein, Young, & Bonner, 1990), which catapulted biomedical research on these unique compounds.

 Cannabinoids refer to both marijuana-derived compounds with the active ingredient of 9-tetrahydrocannabinol (THC) and also the synthetic molecules that activate the same primary targets as THC.

Therapeutic properties of marijuana have been well established; however, the clinical use of either plant-sourced or pure cannabinoids remains limited.

The anticachexia properties of cannabinoids are found in tetrahydrocannabinol (oral capsules of synthetically generated THC) and are used to manage weight loss, wasting syndrome, and nausea and vomiting associated with cancer treatment.”

http://www.ncbi.nlm.nih.gov/pubmed/23448745

Nuvilex Reports Cannabinoid-Based Pancreatic Cancer Treatments to be Developed by Its Subsidiary, Medical Marijuana Sciences, Inc.

“Nuvilex, Inc. (OTCQB:NVLX), international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, announced today its subsidiary, Medical Marijuana Sciences, Inc., is planning to develop treatments for pancreatic cancer based on cannabinoids from Cannabis sativa.

In 2006, in a publication in the prestigious scientific journal Cancer Research, cannabinoids were reported to cause the death of pancreatic cells in laboratory and animal studies; these results were also seen with human pancreatic cancer cells implanted in mice whose immune systems were suppressed. Since then, laboratory studies have shown that when gemcitabine (Gemzar®), the only drug approved by the FDA as a single agent for the treatment of advanced pancreatic cancer, was combined with three different cannabinoids (each used singly), the growth inhibition was more than additive for six different pancreatic cancer cell lines. When these studies were done with human pancreatic cancer cells in immunosuppressed mice, the antitumor effectiveness of gemcitabine was greatly enhanced. These results, combined with those from other studies not mentioned here, indicate the important potential for developing treatments for pancreatic cancer that include the use of cannabinoids.”

More: http://www.nasdaq.com/article/nuvilex-reports-cannabinoid-based-pancreatic-cancer-treatments-to-be-developed-by-its-subsidiary-medical-marijuana-sciences-inc-20130220-00761

Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer.

“The cannabinoid system has been considered to be a potential target of colorectal carcinoma therapy. The aim of this study was to address the correlation between cannabinoid type 1 (CB1) receptor expression and disease severity/outcomes in patients with colorectal cancer (CRC).”

An external file that holds a picture, illustration, etc.
Object name is OL-05-03-0870-g00.jpg

 “…The high immunoreactivity of the cannabinoid type 1 receptor is a significant prognostic factor following surgery in stage IV CRC…

The effect of cannabinoids in colorectal cancer (CRC) has been demonstrated in in vitro experiments and animal models, which indicate the antiproliferative, apoptotic and antimetastatic actions of cannabinoid agonists…

Antineoplastic effects are mediated by the activation of cannabinoid type I (CB1), type 2 (CB2) or a non-cannabinoid receptor-mediated mechanism…”

Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576207/

[Marihuana and cannabinoids as medicaments].

“Biological activity of cannabinoids is caused by binding to two cannabinoid receptors CB1 and CB2. Psychoactive is not only tetrahydrocannabinol (THC) but also: cannabidiol, cannabigerol or cannabichromen. Formerly, the usefulness of hemp was assessed in the relation to temporary appeasement of the symptoms of some ailments as nausea or vomiting.

 Present discoveries indicates that cannabis-based drugs has shown ability to alleviate of autoimmunological disorders such as: Multiple sclerosis (MS), Rheumatoid arthritis (RA) or inflammatory bowel disease. Another studies indicates that cannabinoids play role in treatment of neurological disorders like Alzheimer disease or Amyotrophic lateral sclerosis (ALS) or even can reduce spreading of tumor cells.

 Cannabinoids stand out high safety profile considering acute toxicity, it is low possibility of deadly overdosing and side-effects are comprise in range of tolerated side-effects of other medications.

In some countries marinol and nabilone are used as anti vomiting and nausea drug. First cannabis-based drug containg naturally occurring cannabinoids is Sativex. Sativex is delivered in an mucosal spray for patients suffering from spasticity in MS, pain relevant with cancer and neuropathic pain of various origin. Despite the relatively low acute toxicity of cannabinoids they should be avoid in patients with psychotic disorders, pregnant or breastfeeding woman. Cannabinoids prolong a time of reaction and decrease power of concentration that’s why driving any vehicles is forbidden.

 Cannabis side-effects varies and depend from several factors like administrated dose, rout of administration and present state of mind. After sudden break from long-lasting use, withdrawal symptoms can appear, although they entirely disappear after a week or two.”

http://www.ncbi.nlm.nih.gov/pubmed/23421098

Medical cannabis relieves sufferers of chronic ailments

“Treatment can improve appetite, ease chronic pain, and more, say TAU researchers. Though controversial, medical cannabis has been gaining ground as a valid therapy, offering relief to suffers of diseases such as cancer, Post-Traumatic Stress Disorder, ALS and more. The substance is known to soothe severe pain, increase the appetite, and ease insomnia where other common medications fail.”

More: http://www.virtualmedicalcentre.com/news/medical-cannabis-relieves-sufferers-of-chronic-ailments/18330

Pot Fights Breast Cancer

“For years, cancer patients have used pot to combat the side effects of chemotherapy. But evidence has grown, both clinical and anecdotal, that cannabis has the potential to impede the spread of cancer itself. 

Now, researchers in Japan are reporting that CBDA keeps breast cancer cells from spreading. 

CBD, the miracle of component of cannabis that has been shown to have profound efficacy as a pain reliever, is obtained from its parent molecule, cannabidiolic acid or CBDA.

Until now, investigators have wondered whether CBDA is biologically active. But the study reports: “CBDA is an inhibitor of highly aggressive human breast cancer cell migration.””-

by Dan Skye

http://hightimes.com/news/dskye/7912

More: http://www.sciencedirect.com/science/article/pii/S0378427412012854

Role of cannabinoid and vanilloid receptors in invasion of human breast carcinoma cells.

“It is known that the diversified effects of cannabinoid on the fate of carcinoma cells are mediated predominantly through receptors. However, little is known about the effects of the individual activities of cannabinoid and noncannabinoid receptors. Here we investigate the role of cannabinoid receptor (CB) 1, CB2, and transient receptor potential vanilloid type 1 in cell proliferation and invasion patterns in the MDA-MB-231 cell line.

Our results showed that activation of CB1 and vanilloid receptors by methanandamide, a nonselective agonist, and arachidonyl-2′-choloroethylamide (ACEA) and N-oleoyldopamine, selective agonists, reduced invasion of MDA-MB-231 cells at pharmacological concentrations. Accordingly, CB1 activation resulted in decreased expression of matrix metalloproteinase (MMP) 2. On the other hand, administration of a CB2 agonist (CB65) increased cell invasion and expression of MMP2. The data obtained from MTT assay did not show any correlation between reduced invasion and cytotoxic effects of drugs. In addition, the level of vascular endothelial growth factor was significantly reduced in treatment with (R)-(+)-methanandamide, ACEA, CB65, and AM251 (a potent agonist for GPR55 and selective antagonist of CB1) compared with control. Elevated expression of cyclooxygenase-2 was observed in all of the MDA-MB-231 cells treated with agonists.

These results underline the influence of cannabinoid and vanilloid receptors on the invasiveness of MDA-MB-231 human breast carcinoma cells.”

http://www.ncbi.nlm.nih.gov/pubmed/23394450

The pharmacologic and clinical effects of medical cannabis.

“Cannabis, or marijuana, has been used for medicinal purposes for many years. Several types of cannabinoid medicines are available in the United States and Canada. Dronabinol (schedule III), nabilone (schedule II), and nabiximols (not U.S. Food and Drug Administration approved) are cannabis-derived pharmaceuticals.

Medical cannabis or medical marijuana, a leafy plant cultivated for the production of its leaves and flowering tops, is a schedule I drug, but patients obtain it through cannabis dispensaries and statewide programs. The effect that cannabinoid compounds have on the cannabinoid receptors (CB(1) and CB(2) ) found in the brain can create varying pharmacologic responses based on formulation and patient characteristics. The cannabinoid Δ(9) -tetrahydrocannabinol has been determined to have the primary psychoactive effects; the effects of several other key cannabinoid compounds have yet to be fully elucidated. Dronabinol and nabilone are indicated for the treatment of nausea and vomiting associated with cancer chemotherapy and of anorexia associated with weight loss in patients with acquired immune deficiency syndrome. However, pain and muscle spasms are the most common reasons that medical cannabis is being recommended.

Studies of medical cannabis show significant improvement in various types of pain and muscle spasticity. Reported adverse effects are typically not serious, with the most common being dizziness. Safety concerns regarding cannabis include the increased risk of developing schizophrenia with adolescent use, impairments in memory and cognition, accidental pediatric ingestions, and lack of safety packaging for medical cannabis formulations. This article will describe the pharmacology of cannabis, effects of various dosage formulations, therapeutics benefits and risks of cannabis for pain and muscle spasm, and safety concerns of medical cannabis use.”

http://www.ncbi.nlm.nih.gov/pubmed/23386598